Effects of Almonds on Insulin Sensitivity in Prediabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-20

Study Completion Date

2018-09-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the effects of consuming 1.5 oz almonds twice daily on insulin sensitivity and markers of cardiometabolic health in men and women with prediabetes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Metabolic Effects of Almond Consumption in Adults With Pre-Diabetes

NCT00270985

Prediabetes Insulin Resistance Metabolic Syndrome

COMPLETED PHASE1

Almonds and Cognitive Functions

NCT05322304

PreDiabetes

UNKNOWN NA

Almonds and Diabetes Management

NCT01161030

Type 2 Diabetes

COMPLETED NA

Almond Intervention in Type 2 Diabetes Mellitus

NCT02027740

Cardiovascular Diseases

COMPLETED NA

Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes

NCT04025281

Type 2 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, controlled, two-period crossover study that includes two screening visits, and two 6-week test periods, separated by a 4-week washout. Subjects consume twice daily, 1.5 oz whole, natural almonds (Active Condition) or low-fat foods high in refined starches and added sugars, matched for energy content to the almonds (Control Condition). The assigned study products will be dispensed with instructions to consume 2 servings (Active Product) or 3 servings (Control Products) each day, starting on day 1. Subjects will be screened for prediabetes at the first screening visits. An intravenous glucose tolerance test (IVGTT) will be completed at baseline and the end of each treatment period. Fasting blood samples will be collected for lipid profile and high-sensitivity C-reactive protein (hs-CRP) measurements at all visits. Additionally, blood will be drawn for measurement of Apolipoprotein B and A1, lipoprotein particles and subfractions, Interleukin 6 (IL-6) and Uric acid at the beginning and the end of each test period. Assessments of vital signs, body weight, evaluation of inclusion and exclusion criteria, medication/supplement use, and adverse effects will be performed throughout the study. Compliance will be assessed through a daily log record, and return of unopened study product.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PreDiabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Whole, natural almonds

1.5 oz of whole, natural almonds

Group Type EXPERIMENTAL

1.5 oz of whole, natural almonds

Intervention Type OTHER

1.5 oz of whole, natural almonds

Low-fat, high refined starches/sugars

Low-fat foods,high in refined starches and added sugars

Group Type PLACEBO_COMPARATOR

Low-fat, high refined starches/sugars

Intervention Type OTHER

Low-fat foods, high in refined starches and added sugars

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1.5 oz of whole, natural almonds

Intervention Type OTHER

Low-fat, high refined starches/sugars

Low-fat foods, high in refined starches and added sugars

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. BMI of 25.0-39.9 kg/m2
2. Prediabetic: fingerstick glycated hemoglobin 5.7-6.4% (inclusive), or fasting fingerstick capillary glucose of 100-125 mg/dL (inclusive), or 2-h post-prandial glucose of 140-199 mg/dL.
3. Fasting LDL-C level \<200 mg/dL and fasting TG level \<400 mg/dL.
4. Judged to be in general good health on the basis of medical history and screening laboratory tests.

Exclusion Criteria

1. Atherosclerotic cardiovascular disease including any of the following: clinical signs of atherosclerosis: peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease \[symptomatic (e.g., transient ischemic attack or stroke of carotid origin) or \>50% stenosis on angiography or ultrasound\], history of myocardial infarction, angina, a revascularization procedure, or other forms of clinical atherosclerotic disease (e.g., renal artery disease).
2. History or presence of clinically important pulmonary (including uncontrolled asthma), endocrine (including type I or type II diabetes mellitus), chronic inflammatory disease (including irritable bowel disease, lupus, rheumatoid arthritis), hepatic, renal, hematologic, immunologic, dermatologic, neurologic, psychiatric, or biliary disorders.
3. Known allergy, sensitivity, or intolerance to any ingredients in the study foods.
4. Uncontrolled hypertension.
5. Recent history of cancer, except for non-melanoma skin cancer.
6. Recent change in body weight of ± 4.5 kg (9.9 lbs).
7. Recent use of any medications intended to alter the lipid profile (e.g. bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin (drug form), omega-3-ethyl ester drugs, and/or PCSK9 inhibitors, with the exception of the stable use of statins), weight-loss drugs or programs, systemic corticosteroid drugs, unstable use of any antihypertensive medication; medications known to influence CHO metabolism (e.g. adrenergic receptor blockers, diuretics, and/or hypoglycemic medications).
8. Recent use of food/supplements known to influence lipid metabolism (e.g. omega-3 fatty acid supplements (e.g., flaxseed, fish or algal oils) or fortified foods, sterol/stanol products; dietary supplements (red rice yeast supplements; garlic supplements; soy isoflavone supplements; niacin or its analogues at doses \>400 mg/d, and irregular or inconsistent use of Metamucil® or viscous fiber-containing supplements.
9. Recent use of antibiotics.
10. Pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
11. Extreme dietary habits (e.g. very low CHO diet, vegan, etc.).
12. Current or recent history, or strong potential, for drug or alcohol abuse.
13. History of a diagnosed eating disorder. -

Minimum Eligible Age

18 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No